Reviews - 4xxd mentioned but not cited (3)
- Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Plotkin SS, Cashman NR. Neurobiol Dis 144 105010 (2020)
- Conformational selection in amyloid-based immunotherapy: Survey of crystal structures of antibody-amyloid complexes. Ma B, Zhao J, Nussinov R. Biochim Biophys Acta 1860 2672-2681 (2016)
- Structural biology of cell surface receptors implicated in Alzheimer's disease. Hermans SJ, Nero TL, Morton CJ, Gooi JH, Crespi GAN, Hancock NC, Gao C, Ishii K, Markulić J, Parker MW. Biophys Rev 14 233-255 (2022)
Articles - 4xxd mentioned but not cited (9)
Reviews citing this publication (17)
- Amyloid beta: structure, biology and structure-based therapeutic development. Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE. Acta Pharmacol Sin 38 1205-1235 (2017)
- Protein misfolding in neurodegenerative diseases: implications and strategies. Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, Kopito R, McCampbell A, Leblanc G, Venkateswaran A, Nurmi A, Hodgson R. Transl Neurodegener 6 6 (2017)
- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. van Dyck CH. Biol Psychiatry 83 311-319 (2018)
- Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. Rajasekhar K, Govindaraju T. RSC Adv 8 23780-23804 (2018)
- Passive Aβ Immunotherapy: Current Achievements and Future Perspectives. Schilling S, Rahfeld JU, Lues I, Lemere CA. Molecules 23 E1068 (2018)
- Structural metamorphism and polymorphism in proteins on the brink of thermodynamic stability. Kulkarni P, Solomon TL, He Y, Chen Y, Bryan PN, Orban J. Protein Sci 27 1557-1567 (2018)
- Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Montoliu-Gaya L, Villegas S. Expert Rev Mol Med 18 e13 (2016)
- Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease. Vander Zanden CM, Chi EY. J Pharm Sci 109 68-73 (2020)
- Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Sumner IL, Edwards RA, Asuni AA, Teeling JL. Front Neurosci 12 254 (2018)
- Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. Morató X, Pytel V, Jofresa S, Ruiz A, Boada M. Int J Mol Sci 23 9305 (2022)
- Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases. Rinauro DJ, Chiti F, Vendruscolo M, Limbocker R. Mol Neurodegener 19 20 (2024)
- An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure. Boopathi S, Poma AB, Garduño-Juárez R. Int J Mol Sci 22 10798 (2021)
- Aβ and the dementia syndrome: Simple versus complex perspectives. Hunter S, Smailagic N, Brayne C. Eur J Clin Invest 48 e13025 (2018)
- Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. Decourt B, Noorda K, Noorda K, Shi J, Sabbagh MN. J Exp Pharmacol 14 331-352 (2022)
- Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. Agrawal N, Skelton AA. Protein J 38 425-434 (2019)
- Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis. Pandey G, Ramakrishnan V. Biophys Rev 12 1175-1186 (2020)
- The Impact of Anti-Amyloid Immunotherapies on Stroke Care. Bilodeau PA, Dickson JR, Kozberg MG. J Clin Med 13 1245 (2024)